Radiation Exposure Claims Process Gets Smooth Reinstatement
Published Date: 7/30/2025
Notice
Summary
The Department of Justice is asking to keep collecting info from people filing claims under the Radiation Exposure Compensation Act. This helps folks who got sick from radiation get the money they deserve. They want to make sure the process stays smooth and quick, with no extra costs or delays.
Analyzed Economic Effects
1 provisions identified: 1 benefits, 0 costs, 0 mixed.
RECA Claims Information Collection Continues
The Department of Justice is asking to reinstate and continue collecting the forms needed for claims under the Radiation Exposure Compensation Act (RECA). This collection supports people who got sick from radiation so they can get compensation, and DOJ says it aims to keep the process smooth and quick with no extra costs or delays.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Related Federal Register Documents
2026-11526 — Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128 — Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-09160 — Implementing PATRIOT Act Improvements: Contraband Cigarettes and Smokeless Tobacco
Starting June 8, 2026, new rules crack down harder on illegal cigarette and smokeless tobacco sales. The government lowered the amount that counts as smuggling from 60,000 to just 10,000 cigarettes and now includes smokeless tobacco in the crackdown. Sellers and distributors must keep better records and report more info, making it tougher to dodge the law and protect honest businesses.
2026-12140 — Importer of Controlled Substances Application: Scottsdale Research Institute
Scottsdale Research Institute wants to become an official importer of some controlled substances like ibogaine and marijuana. People who make or import these drugs can share their thoughts or ask for a hearing by July 17, 2026. This move could affect how these substances are brought into the U.S., but no costs or fees are mentioned yet.
2026-12213 — Agency Information Collection Activities; Proposed eCollection eComments Requested; Reinstatement With Change to a Previously Approved Collection Title-International Terrorism Victim Expense Reimbursement Program Application
The Department of Justice is bringing back and updating the application form for the International Terrorism Victim Expense Reimbursement Program. This affects victims of international terrorism who seek help covering their expenses. The DOJ wants your feedback by July 17, 2026, to make sure the form is clear, useful, and easy to fill out—no extra hassle or hidden costs involved!
2026-12144 — Importer of Controlled Substances Application: Wedgewood Pharmacy LLC
Wedgewood Pharmacy LLC wants to become an official importer of certain strong controlled substances, like Etorphine HCL and Thiafentanil. This affects drug manufacturers and others in the supply chain who can comment or request a hearing by July 17, 2026. No direct costs are mentioned, but the decision could impact how these drugs enter the U.S. market.
Previous / Next Documents
Previous: 2025-14343 — Takes of Marine Mammals Incidental to Specified Activities; Taking Marine Mammals Incidental to the Terminal 4 Expansion and Redevelopment Project at the Port of Grays Harbor, Washington
The Port of Grays Harbor got the green light to continue their Terminal 4 Expansion, which might accidentally bother some marine mammals nearby. This project will happen over the next year and involves careful steps to protect sea life while upgrading the port. It’s a big deal for local wildlife and the community, balancing growth with nature’s needs.
Next: 2025-14345 — Arthritis Advisory Committee; Termination
The FDA is ending its Arthritis Advisory Committee because it’s no longer needed. This change affects committee members and anyone who followed its advice, but it won’t cost extra or cause delays. The decision is effective immediately, streamlining how the FDA handles arthritis-related reviews.